On August 24, 2026, Theralase Technologies Inc., a clinical-stage pharmaceutical company focused on developing energy-activated small molecules for the treatment of cancer and infectious diseases, closed a brokered private placement offering under the listed issuer financing exemption for aggregate gross proceeds of approximately C$3.6 million. The offering consisted of 14,812,500 units issued at a price of C$0.24 per unit, with each unit comprising one common share and one common share purchase warrant.
The financing provided Theralase with additional capital to advance its research and development initiatives while utilizing the listed issuer financing exemption to efficiently access the public capital markets. Acting as sole agent and sole bookrunner, Research Capital Corporation played a central role in structuring and executing the transaction, helping facilitate a successful financing for a company operating in the life sciences sector.
Fasken advised Research Capital Corporation with a team led by John Sabetti and included Victoria Zed, Terence Bernard and Yianni Patiniotis (student).
Jurisdiction
- Ontario
